← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro

daratumumab + hyaluronidase-fihj · Janssen Biotech

FDA approvalNew or expanded indicationHigh-risk smoldering multiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with high-risk smoldering multiple myeloma.

LAMPGEN ANALYSIS

Why it matters

The approval introduces an intervention intended to delay progression in a high-risk precursor population before active myeloma develops.

What research teams should watch

Apply explicit high-risk criteria, exclude active myeloma, and balance monitoring visits against burden for asymptomatic participants.

PRIMARY RECORDS

Sources